Danaher (DHR) to Release Quarterly Earnings on Wednesday

Danaher (NYSE:DHR) will likely be announcing its earnings results before the market opens on Wednesday, January 29th. Analysts expect the company to announce earnings of $2.14 per share and revenue of $6,384,506.38 billion for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. Danaher’s revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the company posted $2.02 earnings per share. On average, analysts expect Danaher to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Danaher Trading Up 2.4 %

Danaher stock opened at $244.18 on Wednesday. Danaher has a 52-week low of $225.42 and a 52-week high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $176.36 billion, a price-to-earnings ratio of 46.60, a PEG ratio of 4.30 and a beta of 0.83. The firm has a 50-day moving average price of $234.75 and a two-hundred day moving average price of $253.50.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is currently 20.61%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Raymond James lowered their price target on Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a research report on Tuesday. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target for the company in a report on Friday, December 13th. KeyCorp lifted their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Evercore ISI raised their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, Citigroup dropped their price target on Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average target price of $285.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.